PHARMACOKINETICS OF MIBAVADEMAB (MIBA) IN HEALTHY PARTICIPANTS: RESULTS FROM A RANDOMIZED, PHASE 1, TWO-PART, FIRST-IN-HUMAN STUDY

被引：0
|
作者：
Mendell, J. [1 ]
Gewitz, A. [1 ]
Wang, Y. [1 ]
Harnisch, L. [1 ]
Olenchock, B. [1 ]
Pan, H. [1 ]
Podgrabinska, S. [1 ]
Zheng, W. [1 ]
Zhao, A. [1 ]
Vanhoutte, F. [2 ]
Davis, J. [1 ]
机构：
[1] Regeneron Pharmaceut, Tarrytown, NY USA
[2] SGS Clin Pharmacol Unit, Antwerp, Belgium
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 2023年 / 113卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
PII-074
引用
收藏
页码：S67 / S68
页数：2
相关论文
共 50 条
  • [31] A phase I, first-in-human study to evaluate the safety and tolerability, pharmacokinetics, and pharmacodynamics of MRG-001 in healthy subjects
    Ahmadi, Ali R.
    Atiee, George
    Chapman, Bart
    Reynolds, Laurie
    Sun, John
    Cameron, Andrew M.
    Wesson, Russell N.
    Burdick, James F.
    Sun, Zhaoli
    CELL REPORTS MEDICINE, 2023, 4 (09)
  • [32] A First-in-Human Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of Polyethylene Glycol-Erythropoietin Injection, RD01, in Healthy Volunteers
    Hu, Chaoying
    Li, Jian
    Sun, Wanling
    Zhang, Lan
    BLOOD, 2022, 140 : 2447 - 2448
  • [33] LAPS GLP/GCG Dual Agonist, HM12525A, Confirmed Prolonged Pharmacokinetics in Healthy Volunteers: A First-in-Human Phase 1 Study
    Kang, Jahoon
    DIABETES, 2015, 64 : A46 - A46
  • [34] Safety and pharmacokinetics of IBI112, an IL-23 monoclonal antibody, in Chinese healthy volunteers: a first-in-human phase 1 study
    He, Jinjie
    Du, Weijuan
    Yang, Haijing
    Wang, Jingjing
    Cai, Chenghang
    Ma, Qingyang
    Li, Nanyang
    Yu, Jicheng
    Wu, Xiaojie
    Wu, Jufang
    Chen, Yuancheng
    Cao, Guoying
    Zhang, Jing
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2023, 32 (07) : 669 - 675
  • [35] Cediranib in combination with mFOLFOX6: results from the cohort expansion phase of a two-part Phase I study
    LoRusso, P.
    Zalupski, M.
    Desai, S.
    Burris, H. A.
    Stella, P. J.
    Xu, J.
    Liu, Q.
    Mookerjee, B.
    Shields, A. F.
    EJC SUPPLEMENTS, 2009, 7 (02): : 133 - 133
  • [36] A two-part phase 2 randomized study of dalantercept and axitinib versus placebo plus axitinib in advanced renal cell carcinoma: Results from the part 1 dose escalation cohorts
    Atkins, Michael B.
    Voss, Martin Henner
    Plimack, Elizabeth R.
    Rini, Brian I.
    Alter, Robert
    Dawson, Nancy Ann
    Beck, J. Thaddeus
    Bhatt, Rupal Satish
    Pappas, Kristen M.
    Wilson, Dawn
    McClure, Ty
    Kumar, Ravi
    Attie, Kenneth M.
    Sherman, Matthew L.
    Pandya, Shuchi Sumant
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [37] First-in-human studies of safety, tolerability, pharmacokinetics, and pharmacodynamics of SAR443820, a centrally penetrant RIPK1 inhibitor in healthy participants
    Eastenson, Amy
    Hincelin-Mery, Agnes
    Lewanczyk, Pascale
    Cantalloube, Cathy
    Nicolas, Xavier
    Benamor, Myriam
    Pomponio, Robert
    Krupka, Emmanuel
    Ofengeim, Dimitry
    Xiong, Li
    Atassi, Nazem
    MUSCLE & NERVE, 2022, 66 : S47 - S47
  • [38] A First-in-Human Study To Assess the Safety and Pharmacokinetics of Monoclonal Antibodies against Human Cytomegalovirus in Healthy Volunteers
    Dole, Kiran
    Segal, Florencia Pereyra
    Feire, Adam
    Magnusson, Baldur
    Rondon, Juan C.
    Vemula, Janardhana
    Yu, Jing
    Pang, Yinuo
    Pertel, Peter
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2016, 60 (05) : 2881 - 2887
  • [39] Phase I, two-part, multicenter, first-in-human (FIH) study of DS-6000a in subjects with advanced renal cell carcinoma (RCC) and ovarian tumors (OVC)
    Hamilton, Erika P.
    Jauhari, Shekeab
    Moore, Kathleen N.
    Rini, Brian I.
    McLeod, Robert
    Lin, Jie
    Izumi, Nanae
    Kundu, Madan Gopal
    Myobatake, Yusuke
    Laadem, Abderrahmane
    Noguchi, Yutaka
    Kirui, Julius
    Spigel, David R.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [40] Safety, Pharmacokinetics and Preliminary Efficacy of IL4-Ra Monoclonal Antibody AK120 in Both Healthy and Atopic Dermatitis Subjects: A Phase I, Randomized, Two-Part, Double-Blind, Placebo-Controlled, Dose-Escalation, First-In-Human Clinical Study
    Wynne, Christopher John
    Cole, Alexandra
    Lemech, Charlotte
    Wang, Guoqin
    Zhang, Yu
    Chen, Benchao
    Wang, Max
    Li, Baiyong
    Xia, Michelle
    Sinclair, Rodney
    DERMATOLOGY AND THERAPY, 2023, 13 (10) : 2357 - 2373
12345